{"title":"血清YKL-40水平作为特应性皮炎患者疾病严重程度和治疗反应的生物标志物","authors":"Jiaming Fan, Sijie Zhou, Xinyun Tang, Xuechen Ai, Peimei Zhou","doi":"10.1155/dth/6650241","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Introduction:</b> Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease, and the related biomarkers are still under investigation. Chitinase-3-like protein 1 (YKL-40) is implicated in various inflammatory conditions. This study aimed to explore changes in serum YKL-40 levels in patients with AD and evaluate their correlation with disease severity.</p>\n <p><b>Methods:</b> We enrolled 62 patients with AD (16 with mild, 24 with moderate, and 22 with severe AD) and 62 age- and sex-matched healthy controls. No statistically significant difference in the clinical baseline data was observed between the two groups. Peripheral venous blood samples were collected to assess the serum levels of YKL-40, thymus and activation-regulated chemokine (TARC), interleukin (IL)-4, and IL-13. YKL-40 levels were compared between the groups, and correlations with SCORing Atopic Dermatitis (SCORAD) scores and other serum parameters were analyzed. Patients with moderate-to-severe AD received either traditional treatment (cetirizine hydrochloride and compound glycyrrhizin tablets) or dupilumab for 4 weeks, with comparison of therapeutic effects and serum changes.</p>\n <p><b>Results:</b> Patients with AD exhibited significantly increased serum YKL-40 levels (<i>p</i> < 0.001), which was positively correlated with SCORAD scores (<i>R</i><sup>2</sup> = 0.603, <i>p</i> < 0.001). Serum YKL-40 levels were significantly higher in moderate-to-severe AD patients compared with healthy controls but not in mild AD patients (<i>p</i> = 0.094). In addition, TARC, IgE, IL-4, and IL-13 levels were increased in patients with AD (<i>p</i> < 0.001), with strong correlations to YKL-40. Dupilumab treatment significantly reduced visual analog scale scores for itching (<i>p</i> = 0.016) and YKL-40, IL-4, and IL-13 levels (<i>p</i> < 0.05).</p>\n <p><b>Conclusions:</b> YKL-40 levels were elevated in patients with AD and are correlated with disease severity and IL-4, IL-13, and TARC levels. Dupilumab effectively lowers YKL-40 and inflammatory markers, showing therapeutic benefit.</p>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6650241","citationCount":"0","resultStr":"{\"title\":\"Serum YKL-40 Levels as a Biomarker for Disease Severity and Therapeutic Response in Atopic Dermatitis Patients\",\"authors\":\"Jiaming Fan, Sijie Zhou, Xinyun Tang, Xuechen Ai, Peimei Zhou\",\"doi\":\"10.1155/dth/6650241\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><b>Introduction:</b> Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease, and the related biomarkers are still under investigation. Chitinase-3-like protein 1 (YKL-40) is implicated in various inflammatory conditions. This study aimed to explore changes in serum YKL-40 levels in patients with AD and evaluate their correlation with disease severity.</p>\\n <p><b>Methods:</b> We enrolled 62 patients with AD (16 with mild, 24 with moderate, and 22 with severe AD) and 62 age- and sex-matched healthy controls. No statistically significant difference in the clinical baseline data was observed between the two groups. Peripheral venous blood samples were collected to assess the serum levels of YKL-40, thymus and activation-regulated chemokine (TARC), interleukin (IL)-4, and IL-13. YKL-40 levels were compared between the groups, and correlations with SCORing Atopic Dermatitis (SCORAD) scores and other serum parameters were analyzed. Patients with moderate-to-severe AD received either traditional treatment (cetirizine hydrochloride and compound glycyrrhizin tablets) or dupilumab for 4 weeks, with comparison of therapeutic effects and serum changes.</p>\\n <p><b>Results:</b> Patients with AD exhibited significantly increased serum YKL-40 levels (<i>p</i> < 0.001), which was positively correlated with SCORAD scores (<i>R</i><sup>2</sup> = 0.603, <i>p</i> < 0.001). Serum YKL-40 levels were significantly higher in moderate-to-severe AD patients compared with healthy controls but not in mild AD patients (<i>p</i> = 0.094). In addition, TARC, IgE, IL-4, and IL-13 levels were increased in patients with AD (<i>p</i> < 0.001), with strong correlations to YKL-40. Dupilumab treatment significantly reduced visual analog scale scores for itching (<i>p</i> = 0.016) and YKL-40, IL-4, and IL-13 levels (<i>p</i> < 0.05).</p>\\n <p><b>Conclusions:</b> YKL-40 levels were elevated in patients with AD and are correlated with disease severity and IL-4, IL-13, and TARC levels. Dupilumab effectively lowers YKL-40 and inflammatory markers, showing therapeutic benefit.</p>\\n </div>\",\"PeriodicalId\":11045,\"journal\":{\"name\":\"Dermatologic Therapy\",\"volume\":\"2025 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-06-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6650241\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologic Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/dth/6650241\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/6650241","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Serum YKL-40 Levels as a Biomarker for Disease Severity and Therapeutic Response in Atopic Dermatitis Patients
Introduction: Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease, and the related biomarkers are still under investigation. Chitinase-3-like protein 1 (YKL-40) is implicated in various inflammatory conditions. This study aimed to explore changes in serum YKL-40 levels in patients with AD and evaluate their correlation with disease severity.
Methods: We enrolled 62 patients with AD (16 with mild, 24 with moderate, and 22 with severe AD) and 62 age- and sex-matched healthy controls. No statistically significant difference in the clinical baseline data was observed between the two groups. Peripheral venous blood samples were collected to assess the serum levels of YKL-40, thymus and activation-regulated chemokine (TARC), interleukin (IL)-4, and IL-13. YKL-40 levels were compared between the groups, and correlations with SCORing Atopic Dermatitis (SCORAD) scores and other serum parameters were analyzed. Patients with moderate-to-severe AD received either traditional treatment (cetirizine hydrochloride and compound glycyrrhizin tablets) or dupilumab for 4 weeks, with comparison of therapeutic effects and serum changes.
Results: Patients with AD exhibited significantly increased serum YKL-40 levels (p < 0.001), which was positively correlated with SCORAD scores (R2 = 0.603, p < 0.001). Serum YKL-40 levels were significantly higher in moderate-to-severe AD patients compared with healthy controls but not in mild AD patients (p = 0.094). In addition, TARC, IgE, IL-4, and IL-13 levels were increased in patients with AD (p < 0.001), with strong correlations to YKL-40. Dupilumab treatment significantly reduced visual analog scale scores for itching (p = 0.016) and YKL-40, IL-4, and IL-13 levels (p < 0.05).
Conclusions: YKL-40 levels were elevated in patients with AD and are correlated with disease severity and IL-4, IL-13, and TARC levels. Dupilumab effectively lowers YKL-40 and inflammatory markers, showing therapeutic benefit.
期刊介绍：
Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
